Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Operating Expenses: 2013-2025

Historic Other Operating Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $16.9 million.

  • Amphastar Pharmaceuticals' Other Operating Expenses rose 49.55% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 25.21%. This contributed to the annual value of $37.8 million for FY2024, which is 31.02% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Other Operating Expenses is $16.9 million, which was up 64.88% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Other Operating Expenses registered a high of $16.9 million during Q3 2025, and its lowest value of $4.1 million during Q4 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Other Operating Expenses had a median value of $10.2 million in 2024 and averaged $9.9 million.
  • Data for Amphastar Pharmaceuticals' Other Operating Expenses shows a peak YoY skyrocketed of 76.12% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Other Operating Expenses stood at $4.1 million in 2021, then soared by 34.28% to $5.5 million in 2022, then spiked by 57.51% to $8.6 million in 2023, then rose by 20.94% to $10.4 million in 2024, then soared by 49.55% to $16.9 million in 2025.
  • Its Other Operating Expenses was $16.9 million in Q3 2025, compared to $10.2 million in Q2 2025 and $11.9 million in Q1 2025.